Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (NYSE: INSP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Inspire is a medical technology company focused on the Inspire system, the first and only FDA-approved closed-loop neurostimulation therapy for moderate to severe obstructive sleep apnea (OSA). The company sells primarily to hospitals and ambulatory surgery centers in the U.S., Europe, and Asia.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue | $802.8 million | $624.8 million | +28.5% |
| Gross Profit | $679.8 million | $528.2 million | +28.7% |
| Gross Margin | 84.7% | 84.5% | +0.2 pts |
| Operating Income | $36.1 million | ($40.3 million) loss | Turnaround |
| Net Income | $53.5 million | ($21.2 million) loss | Turnaround |
| EPS (Diluted) | $1.75 | ($0.72) | N/A |
| Cash & Investments | $516.5 million | $469.5 million | +10.0% |
| Operating Cash Flow | $130.2 million | $24.7 million | +427% |
| Working Capital | $542.3 million | $515.6 million | +5.2% |
Debt: The company has no outstanding long-term debt as of December 31, 2024, having prepaid its former credit facility in August 2022.
Material Changes vs. Prior Period
- Profitability Milestone: 2024 marked the company's first year of net income ($53.5 million), reversing a net loss of $21.2 million in 2023. This was driven by significant revenue growth and improved operating leverage.
- Revenue Growth: Revenue increased 28.5% to $802.8 million. U.S. revenue grew 27.2% to $771.0 million, while international revenue surged 70.6% to $31.8 million, recovering from supply chain disruptions in Europe experienced in late 2023.
- Expense Management: Research and Development (R&D) expenses decreased 2.1% to $114.1 million due to reduced ongoing development costs for next-generation products, partially offset by higher compensation. Selling, General, and Administrative (SG&A) expenses increased 17.2% to $529.6 million, primarily due to headcount expansion and stock-based compensation.
- Share Repurchases: In November 2024, the company entered an Accelerated Share Repurchase (ASR) agreement, paying $75.0 million to repurchase approximately 409,043 shares (final settlement in Jan 2025).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Product Launch: The company received FDA approval for its next-generation Inspire system in August 2024 and expects a full U.S. launch in 2025.
- Reimbursement: Medicare reimbursement rates for 2025 were announced in November 2024, showing a 3% increase for hospital outpatient implants and a 4% increase for ASCs.
- Competition: Management notes the FDA approval of Zepbound (tirzepatide) for OSA treatment in December 2024. While acknowledging potential competition, the company believes GLP-1 drugs may reduce patient BMI, potentially expanding the pool of eligible candidates for Inspire therapy.
- Capital Allocation: The Board authorized a $150 million share repurchase program in August 2024. The company expects to maintain direct-to-consumer marketing expenditures and continue expanding its sales force.
Risks and Contingencies
- Government Investigation: On January 17, 2025, the company received a Civil Investigative Demand (CID) from the DOJ regarding allegations of false claims and Anti-Kickback Statute violations related to marketing and reimbursement practices. The company is cooperating, but the outcome is uncertain.
- Legal Proceedings: The company is defending a securities class action lawsuit filed in December 2023 regarding prior authorization disclosures. A related stockholder derivative lawsuit was filed in July 2024 but a motion for voluntary dismissal was filed in September 2024.
- Supply Chain: The company relies on single-source suppliers. While a polyurethane lead shortage in Europe (late 2023/early 2024) has been resolved via EU MDR certification of silicone leads, future disruptions remain a risk.
- Regulatory: Ongoing compliance with FDA and EU Medical Device Regulations (MDR) is critical. Delays in certification can impact revenue, as seen in the 2023/2024 European supply issue.
Key Facts for Investor Verification
- First-Year Profitability: Verify the sustainability of the $53.5 million net income given the significant increase in SG&A expenses ($529.6 million) relative to revenue growth.
- DOJ Investigation: Monitor the status and potential financial impact of the January 2025 DOJ Civil Investigative Demand regarding False Claims Act allegations.
- Next-Gen Launch: Track the commercial rollout and market adoption of the next-generation Inspire system scheduled for 2025.
- GLP-1 Impact: Assess the long-term competitive impact of FDA-approved GLP-1 drugs (e.g., Zepbound) on the OSA treatment market and Inspire's patient eligibility criteria.
- Share Repurchase Execution: Confirm the final settlement details and total share count of the $75 million ASR agreement settled in January 2025.